| Literature DB >> 27506582 |
Xiju Shi1, Xuming Liu2, Qin Wang3, Amaresh Das4, Guiping Ma5, Lu Xu3, Qing Sun2, Lalitha Peddireddi2, Wei Jia4, Yanhua Liu5, Gary Anderson2, Jianfa Bai6, Jishu Shi7.
Abstract
Mixed infection with different pathogens is common in swine production systems especially under intensive production conditions. Quick and accurate detection and differentiation of different pathogens are necessary for epidemiological surveillance, disease management and import and export controls. In this study, we developed and validated a panel of multiplex real-time PCR/RT-PCR assays composed of four subpanels, each detects three common swine pathogens. The panel detects 12 viruses or viral serotypes, namely, VSV-IN, VSV-NJ, SVDV, CSFV, ASFV, FMDV, PCV2, PPV, PRV, PRRSV-NA, PRRSV-EU and SIV. Correlation coefficients (R(2)) and PCR amplification efficiencies of all singular and triplex real-time PCR reactions are within the acceptable range. Comparison between singular and triplex real-time PCR assays of each subpanel indicates that there is no significant interference on assay sensitivities caused by multiplexing. Specificity tests on 226 target clinical samples or 4 viral strains and 91 non-target clinical samples revealed that the real-time PCR panel is 100% specific, and there is no cross amplification observed. The limit of detection of each triplex real-time PCR is less than 10 copies per reaction for DNA, and less than 16 copies per reaction for RNA viruses. The newly developed multiplex real-time PCR panel also detected different combinations of co-infections as confirmed by other means of detections.Entities:
Keywords: Diagnostic; Panel assay; RT-PCR; Real-time PCR; Swine viruses
Mesh:
Year: 2016 PMID: 27506582 PMCID: PMC7119729 DOI: 10.1016/j.jviromet.2016.08.005
Source DB: PubMed Journal: J Virol Methods ISSN: 0166-0934 Impact factor: 2.014
Primers and probes used in the multiplex real time PCR/RT-PCR panel assay.
| Subpanel | Virus | Target gene | Product size | # of Sequences used | Primers/ | Sequences (5′-3′) |
|---|---|---|---|---|---|---|
| 1 | PRV | gE | 98 bp | 138 | FP | CGGTGCCTGCTGTACTACG |
| RP | GGCGAGGTGAAGCTGCA | |||||
| Probe | Cy5- CGAGCCCTGCATCTACCACC-BHQ2 | |||||
| PPV | NS1 | 124 bp | 97 | FP | AGCGAGCCAACAACACCA | |
| RP | CACCAAAGCAGGCTCTTATGTC | |||||
| Probe | MAX-ACCAACCTGCACTTAACTCCAACA-BHQ1 | |||||
| PCV2 | ORF2 | 124 bp | 2673 | FP1 | ACGGATATTGTAKTCCTGGTCGT | |
| RP1 | CTTCCAACCMAAYAACAAAAGRAATCA | |||||
| RP2 | ACTTCCAACCAAATAACAAAAGAAATCAG | |||||
| RP3 | CCAACCAAACAACAAAAGAAACCA | |||||
| Probe | FAM-CAGTGCCGAGGCCTACRTG-BHQ1 | |||||
| 2 | SVDV | 5′UTR | 111 bp | 47 | FP | TCCTCCGGCCCCTGAAT |
| RP | ACACCCAAAGTAGTCGGTTCC | |||||
| Probe | MAX-CACCAGTGGGCAGTCTGTCG-BHQ1 | |||||
| VSV-IN | L | 141 bp | 38 | FP | TGATGATGCATGATCCWGCTCT | |
| RP | ACACWCCTCCAATGGAAGGGT | |||||
| Probe | FAM-ACCGGGCTTGCACAGTTCTAC-BHQ1 | |||||
| VSV-NJ | L | 141 bp | 43 | FP 1 | GCTCTTTATGCATGACCCTGC | |
| FP 2 | TGCTTTTTATGCATGACCCWGC | |||||
| RP | CGAGACAACGCCATACCACA | |||||
| Probe | Cy5-CTGGTTTGCACACCAGAACATTCA-BHQ2 | |||||
| 3 | ASFV | VP72 | 145 bp | 483 | FP1 | GCGATGATGATTACCTTTGCTTTG |
| FP 2 | CGATGATGATTACCTTCGCTTTGA | |||||
| RP 1 | CGATACCACAAGATCAGCCGT | |||||
| RP 2 | CTGATACCACAAGATCAGCCGT | |||||
| RP 3 | GATACCACAAGATCGGCCGT | |||||
| Probe | MAX-CACGGGAGGAATACCAACCCAG-BHQ1 | |||||
| CSFV | 5′UTR | 110 bp | 364 | FP 1 | AGCCCACCTCGAGATGCTA | |
| FP 2 | AGCCCACCTCGATATGCTATG | |||||
| FP3 | AGCTCACCTCGAGATGCTATG | |||||
| RP 1 | CTATCAGGTCGTACTCCCATCAC | |||||
| RP 2 | TATCAGGTCGTACCCCCATCA | |||||
| Probe | Cy5-ACGAGGGCAWGCCCAAGAC-BHQ2 | |||||
| FMDV | 3D | 99 bp | 5888 | FP1 | ACTGGGTTTTACAAACCTGTGATG | |
| FP 2 | CTGGGTTTTATAAACCTGTGATGGC | |||||
| RP 1 | CCACGGAGATCAACTTCTCCT | |||||
| RP 2 | TGCCACAGAGATCAACTTCTCC | |||||
| RP3 | CCACGGAAATCAACTTCTCCTG | |||||
| Probe | FAM-TCTCCTTTGCACGCCGTGG-BHQ1 | |||||
| 4 | SIV | M | 83 bp | 1528 | FP 1 | CCTGTCACCTCTGACTAAGGG |
| FP 2 | ATCCTGTCACCTCTGACTAAAGG | |||||
| FP 3 | ATCTTGTCACCTCTGACTAAGGG | |||||
| FP 4 | CCTGTCACCTCTGACCAAGG | |||||
| RP 1 | CGTCTACGCTGCAGTCCTC | |||||
| RP 2 | CGTCTACGCTGWAGTCCTCG | |||||
| RP 3 | CGTCTACGtTGCAGTCCTCG | |||||
| Probe | Cy5-ACGCTCACCGTGCCSAG-BHQ2 | |||||
| PRRSV-NA | ORF7 | 111 bp | 989 | FP 1 | CCAGCCWGTCAATCAGCTGT | |
| FP 2 | CCAGCCGGTCAATCAGCT | |||||
| FP 3 | CCAGCCAGTCAACCAGCT | |||||
| RP 1 | GGCTTCTCCGGGTTTTTCTTY | |||||
| RP2 | GGCTTCTCCGGGCTTTTCT | |||||
| RP3 | GGGCTTCTCCGGGTTTTTATTC | |||||
| Probe 1 | FAM-CGGTCCCTTGCCTCTGGAC-BHQ1 | |||||
| Probe 2 | FAM-CCGGTCCCTTRCCTCTRGACT-BHQ1 | |||||
| PRRSV-EU | ORF7 | 133 bp | 779 | FP 1 | CCAGCCAGTCAATCAACTGTG | |
| FP 2 | GCCAGTCAGTCAATCAACTGTG | |||||
| FP 3 | CCAGCCAGTCAATCAGCTGT | |||||
| FP 4 | GCCAGTCAGTCAATCAGCTGT | |||||
| RP 1 | TCATCTTCWGCAGCCAGGG | |||||
| RP 2 | TCATCTTCAGCAGCCAAGGG | |||||
| RP 3 | TCATCTTCAGCAGCTAGGGGA | |||||
| RP4 | TCATCTTCAGCAGCTAAGGGAAA | |||||
| Probe | MAX-TGATRAARTCCCAGCGCCAGC-BHQ1 |
*FP: Forward primer; RP: Reverse primer.
Analytical sensitivity and limit of detection of the singular and triplex assays analyzed by standard curves using plasmid DNA or RNA as templates.
| Virus | PCR Type | Plasmid DNA | RNA | ||||
|---|---|---|---|---|---|---|---|
| R2 | E | LOD | R2 | E | LOD | ||
| PRV | Singular | 0.998 | 95.20% | 5 | N/A | N/A | N/A |
| Triplex | 0.992 | 100.80% | 6 | N/A | N/A | N/A | |
| PPV | Singular | 0.991 | 105.00% | 3 | N/A | N/A | N/A |
| Triplex | 0.996 | 97.30% | 5 | N/A | N/A | N/A | |
| PCV-2 | Singular | 0.998 | 90.40% | 1 | N/A | N/A | N/A |
| Triplex | 0.991 | 93.70% | 2 | N/A | N/A | N/A | |
| SVDV | Singular | 0.998 | 108.70% | 2 | 0.997 | 94.2% | 5 |
| Triplex | 0.994 | 98.10% | 2 | 0.981 | 91.3% | 5 | |
| VSV-IN | Singular | 0.997 | 106.90% | 6 | 0.992 | 102.7% | 5 |
| Triplex | 0.997 | 96.10% | 7 | 0.996 | 94.9% | 14 | |
| VSV-NJ | Singular | 0.997 | 103.70% | 4 | 0.995 | 92.5% | 5 |
| Triplex | 0.999 | 98.60% | 8 | 0.996 | 96.9% | 10 | |
| ASFV | Singular | 0.992 | 107.20% | 1 | N/A | N/A | N/A |
| Triplex | 0.999 | 95.90% | 3 | N/A | N/A | N/A | |
| CSFV | Singular | 0.998 | 90.90% | 3 | 0.999 | 110.2% | 6 |
| Triplex | 0.994 | 91.00% | 4 | 0.994 | 92.2% | 16 | |
| FMDV | Singular | 0.998 | 100.30% | 5 | 0.998 | 102.9% | 5 |
| Triplex | 0.998 | 98.40% | 5 | 0.982 | 93.6% | 5 | |
| SIV | Singular | 0.999 | 98.4% | 1 | 0.995 | 94.7% | N/A |
| Triplex | 0.998 | 105.3% | 3 | 0.996 | 110.3% | N/A | |
| PRRSV-NA | Singular | 0.999 | 99.00% | 3 | 0.997 | 99.2% | N/A |
| Triplex | 0.997 | 92.50% | 5 | 0.995 | 107.6% | N/A | |
| PRRSV-EU | Singular | 1.000 | 99.90% | 2 | 0.990 | 103.9% | N/A |
| Triplex | 0.998 | 105.30% | 3 | 0.998 | 103.6% | N/A | |
R2: Correlation coefficient; E: PCR amplification efficiency (calculated by E = 10−1/slope-1); LOD: Limit of detection (Copies/μL).
Correlation of sensitivities between triplex assays and singular assays using Ct values generated with 10-fold serial dilutions of plasmid DNA or RNA.
| Virus | Correlation coefficient (R2) | |
|---|---|---|
| Plasmid DNA | RNA | |
| PRV | 0.998 | N/A |
| PPV | 0.998 | N/A |
| PCV-2 | 0.972 | N/A |
| SVDV | 0.995 | 0.982 |
| VSV-IN | 0.996 | 0.997 |
| VSV-NJ | 0.999 | 0.991 |
| ASFV | 0.985 | N/A |
| CSFV | 0.978 | 0.976 |
| FMDV | 0.998 | 0.991 |
| SIV | 0.994 | 0.993 |
| PRRSV-NA | 0.999 | 0.998 |
| PRRSV-EU | 0.998 | 0.975 |
R2: Correlation coefficient of Ct values detected with triplex assay and singular assays using plasmid DNA or RNA samples.
Comparison among the newly developed triplex SIV, PRRSV-NA and PRRSV-EU real time RT-PCR assay with existing real time RT-PCR assays using clinical samples.
| Clinical samples | Target | Newly developed real time RT-PCR | KSU real time RT-PCR | ||||
|---|---|---|---|---|---|---|---|
| Triplex of SIV/PRRSV-NA/PRRSV-EU | SIV singular | PRRSV-NA singular | PRRSV-EU singular | PRRSV | SIV | ||
| 80 sera | SIV | 1 | 1 | 0 | 0 | NT | NT |
| PRRSV-NA | 43 | 0 | 43 | 0 | 44 | NT | |
| PRRSV-EU | 1 | 0 | 0 | 1 | |||
| SIV + PRRSV-NA | 5 | 5 | 5 | 0 | NT | NT | |
| 53 lung tissues | SIV | 28 | 28 | 0 | 0 | NT | 28 |
| PRRSV-NA | 3 | 0 | 3 | 0 | NT | NT | |
| PRRSV-EU | 0 | 0 | 0 | 0 | NT | NT | |
| SIV + PRRSV-NA | 5 | 5 | 5 | 0 | NT | NT | |
NT: Not tested.
Comparison among the newly developed triplex PPV, PRV and PCV-2 real time PCR assay with existing real time PCR assays using clinical samples.
| Clinical samples | Positive target(s) | Newly developed real time PCR | BJCIQ real time PCR | |||||
|---|---|---|---|---|---|---|---|---|
| Triplex of PPV, PRV and PCV-2 | PPV singular | PRV singular | PCV-2 singular | PPV | PRV | PCV-2 | ||
| 24 tonsil tissues positive for PPV | PPV | 24 | 24 | 0 | 0 | 24 | NT | NT |
| PRV | 3 | 0 | 3 | 0 | NT | NT | NT | |
| PCV-2 | 12 | 0 | 0 | 12 | NT | NT | NT | |
| PPV + PRV | 3 | 3 | 3 | 0 | NT | NT | NT | |
| PPV + PCV-2 | 12 | 12 | 0 | 12 | NT | NT | NT | |
| PRV + PCV-2 | 3 | 0 | 3 | 3 | NT | NT | NT | |
| PPV + PRV + PCV-2 | 3 | 3 | 3 | 3 | NT | NT | NT | |
| 24 tonsil tissues positive for PCV-2 | PPV | 10 | 10 | 0 | 0 | NT | NT | NT |
| PRV | 4 | 0 | 4 | 0 | NT | NT | NT | |
| PCV-2 | 24 | 0 | 0 | 24 | NT | NT | 24 | |
| PPV + PRV | 4 | 4 | 4 | 0 | NT | NT | NT | |
| PPV + PCV-2 | 10 | 10 | 0 | 10 | NT | NT | NT | |
| PRV + PCV-2 | 4 | 0 | 4 | 4 | NT | NT | NT | |
| PPV + PRV + PCV-2 | 4 | 4 | 4 | 4 | NT | NT | NT | |
| 16 lung tissues positive for PRV | PPV | 8 | 8 | 0 | 0 | NT | NT | NT |
| PRV | 14 | 0 | 14 | 0 | NT | 16 | NT | |
| PCV-2 | 5 | 0 | 0 | 5 | NT | NT | NT | |
| PPV + PRV | 7 | 7 | 7 | 0 | NT | NT | NT | |
| PPV + PCV-2 | 5 | 5 | 0 | 5 | NT | NT | NT | |
| PRV + PCV-2 | 5 | 0 | 5 | 5 | NT | NT | NT | |
| PPV + PRV + PCV-2 | 1 | 1 | 1 | 1 | NT | NT | NT | |
NT: Not tested. BJCIQ: Beijing Entry & Exit Inspection and Quarantine Bureau.
Comparison between the newly developed triplex FMDV, CSFV and ASFV real time RT-PCR with virus isolation and existing real time RT-PCR assay on clinical samples.
| Clinical samples | Target | Newly developed real time RT-PCR triplex assay of FMDV/CSFV/ASFV | CNCSFVRL/CNFMDVRL/FADDL-USDA | |||||
|---|---|---|---|---|---|---|---|---|
| Real-time RT-PCR | Virus isolation | |||||||
| FMDV | ASFV | CSFV | FMDV | ASFV | CSFV | |||
| 15 lymph nodes positive for FMDV | FMDV | 15 | 15 | NT | NT | 15 | NT | NT |
| CSFV | 0 | NT | NT | NT | NT | NT | NT | |
| ASFV | 0 | NT | NT | NT | NT | NT | NT | |
| 14 lung tissues positive for CSFV | FMDV | 0 | NT | NT | NT | NT | NT | NT |
| CSFV | 14 | NT | NT | 14 | NT | NT | 14 | |
| ASFV | 0 | NT | NT | NT | NT | NT | NT | |
| 4 ASFV isolates | FMDV | 0 | NT | NT | NT | NT | NT | NT |
| CSFV | 0 | NT | NT | NT | NT | NT | NT | |
| ASFV | 4 | NT | 4 | NT | NT | 4 | NT | |
CNCSFRL: Chinese National Classical Swine Fever Reference Laboratory; CNFMDRL: Chinese National Foot and Mouth Disease Reference Laboratory; FADDL: Foreign Animal Disease Diagnostic Laboratory, NVSL, APHIS, USDA.
NT: Not tested.